Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

Julie E Ledgerwood¹

Affiliations

Affiliation

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, USA. Electronic address: ledgerwood@mail.nih.gov.

PMID: 26248511
DOI: 10.1016/S1473-3099(15)00222-4

Comment

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

Julie E Ledgerwood. Lancet Infect Dis. 2015 Oct.

. 2015 Oct;15(10):1117-1119.

doi: 10.1016/S1473-3099(15)00222-4. Epub 2015 Aug 4.

Author

Julie E Ledgerwood¹

Affiliation

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US Department of Health and Human Services, Bethesda, MD, USA. Electronic address: ledgerwood@mail.nih.gov.

PMID: 26248511
DOI: 10.1016/S1473-3099(15)00222-4

No abstract available

PubMed Disclaimer

Comment on

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.
Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium. Huttner A, et al. Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4. Lancet Infect Dis. 2015. PMID: 26248510 Free PMC article. Clinical Trial.

Cited by

Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation.
Schieffelin J, Moses LM, Shaffer J, Goba A, Grant DS. Schieffelin J, et al. Clin Trials. 2016 Feb;13(1):66-72. doi: 10.1177/1740774515621013. Epub 2016 Jan 14. Clin Trials. 2016. PMID: 26768566 Free PMC article.
Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
Agnandji ST, Fernandes JF, Bache EB, Obiang Mba RM, Brosnahan JS, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Krähling V, Biedenkopf N, Fehling SK, Strecker T, Clark DJ, Staines HM, Hooper JW, Silvera P, Moorthy V, Kieny MP, Adegnika AA, Grobusch MP, Becker S, Ramharter M, Mordmüller B, Lell B; VEBCON Consortium; Krishna S, Kremsner PG. Agnandji ST, et al. PLoS Med. 2017 Oct 6;14(10):e1002402. doi: 10.1371/journal.pmed.1002402. eCollection 2017 Oct. PLoS Med. 2017. PMID: 28985239 Free PMC article. Clinical Trial.
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
Pushparajah D, Jimenez S, Wong S, Alattas H, Nafissi N, Slavcev RA. Pushparajah D, et al. Adv Drug Deliv Rev. 2021 Mar;170:113-141. doi: 10.1016/j.addr.2021.01.003. Epub 2021 Jan 7. Adv Drug Deliv Rev. 2021. PMID: 33422546 Free PMC article. Review.
A Replicating Single-Cycle Adenovirus Vaccine Against Ebola Virus.
Anguiano-Zarate SS, Matchett WE, Nehete PN, Sastry JK, Marzi A, Barry MA. Anguiano-Zarate SS, et al. J Infect Dis. 2018 Nov 5;218(12):1883-1889. doi: 10.1093/infdis/jiy411. J Infect Dis. 2018. PMID: 29982595 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

Affiliation

Use of low dose rVSV-ZEBOV: safety issues in a Swiss cohort

Author

Affiliation

Comment on

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical